Safety And Efficacy Assessment of the zLock Facet Fusion System- A Pilot Study
Primary Purpose
Low Back Pain
Status
Active
Phase
Not Applicable
Locations
Hungary
Study Type
Interventional
Intervention
zLOCK Facet Stabilization System
Sponsored by
About this trial
This is an interventional treatment trial for Low Back Pain focused on measuring stabilization, facet arthritis, spondylolisthesis, stenosis
Eligibility Criteria
Inclusion Criteria:
Patient is scheduled for spine surgery with at least one of the following:
When used in adjunct to an intervertebral front cage:
- Degenerative Spondylolisthesis up to grade 2
- Mild to Moderate Degenerative disc disease (DDD)
- Degeneration of the facets - following validating the pain source by facet injection.
When used stand-alone:
- Degenerative Spondylolisthesis grade 1-2
- Moderate to severe Stenosis with listhesis
- Moderate to severe stenosis without listhesis (in cases that the investigator determines stabilization is required).
- Degeneration of the facets- following validating the pain source by facet injection.
- Claudication due to moderate to severe stenosis (central/ foraminal) as verified by imaging.
- 18< Age < 75
- Weight < 100Kg
- Signed informed consent form
- At least 3 months of unsuccessful conventional treatments
Exclusion Criteria:
- Fusion procedure performed or required in more than one inter-vertebrae space.
- Active systemic infection or infection localized to the site of the proposed implantation are contraindications to implantation.
- Osteoporosis
- Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place.
- Any entity or conditions that totally preclude the possibility of fusion, i.e., cancer, kidney dialysis, or osteopenia, are relative contraindications.
- Obesity (BMI ≥30)
- Foreign body sensitivity
- Alcoholism, or drug abuse
- Subject with a cardiac pacemaker or other implanted electro medical device
- Subject with known condition of drug abuse and/or alcoholism
- Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception)
- Concurrent participation in another clinical trial using any investigational drug or device.
- Mental disorders.
Sites / Locations
- Pecs University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
zLock Facet Locking Implant System
Arm Description
Outcomes
Primary Outcome Measures
Safety assessment - no device related reoperation
The safety of the zLOCK Facet Implant System will be established based on the absence of device related reoperations.
Secondary Outcome Measures
Efficacy assessment - achieving facet fusion 12 months post procedure
The efficacy of using the zLOCK System will be determined by achieving facet fusion 12 months post procedure.
Patient is defined "success" if facet fusion is achieved at 12 months post procedure.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04229316
Brief Title
Safety And Efficacy Assessment of the zLock Facet Fusion System- A Pilot Study
Official Title
Safety And Efficacy Assessment of the zLock Facet Fusion System- A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 12, 2018 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
June 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ZygoFix
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
ZygoFix has developed a system consisting of zLOCK Facet Fusion System. The zLOCK Facet Fusion System is intended for single level stabilization of a spinal motion segment to promote bonny fusion of the joint. The system is designed for percutaneous deployment. The zLOCK implant is designed to be deployed in the facet joint thereby utilizing the body's natural mechanical structure without adding an external scaffold (see figure below).
The zLOCK implant is inserted into the facet joint space while it adapts to the joint's changing geometry. Stabilization is achieved by firm grip of each joint bone and resisting to any relative motion. The zLOCK implant is placed percutaneously and requires only one incision per side, thereby reducing the invasiveness, procedure duration and shorten the recovery period.
This pilot study was designed in order to assess the safety and effectiveness of the zLOCK system.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain
Keywords
stabilization, facet arthritis, spondylolisthesis, stenosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
zLock Facet Locking Implant System
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
zLOCK Facet Stabilization System
Intervention Description
zLOCK Facet Stabilization System is a device intended to provide posterior stability in lumbar spine in order to reduce lumbar back pains
Primary Outcome Measure Information:
Title
Safety assessment - no device related reoperation
Description
The safety of the zLOCK Facet Implant System will be established based on the absence of device related reoperations.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Efficacy assessment - achieving facet fusion 12 months post procedure
Description
The efficacy of using the zLOCK System will be determined by achieving facet fusion 12 months post procedure.
Patient is defined "success" if facet fusion is achieved at 12 months post procedure.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is scheduled for spine surgery with at least one of the following:
When used in adjunct to an intervertebral front cage:
Degenerative Spondylolisthesis up to grade 2
Mild to Moderate Degenerative disc disease (DDD)
Degeneration of the facets - following validating the pain source by facet injection.
When used stand-alone:
Degenerative Spondylolisthesis grade 1-2
Moderate to severe Stenosis with listhesis
Moderate to severe stenosis without listhesis (in cases that the investigator determines stabilization is required).
Degeneration of the facets- following validating the pain source by facet injection.
Claudication due to moderate to severe stenosis (central/ foraminal) as verified by imaging.
18< Age < 75
Weight < 100Kg
Signed informed consent form
At least 3 months of unsuccessful conventional treatments
Exclusion Criteria:
Fusion procedure performed or required in more than one inter-vertebrae space.
Active systemic infection or infection localized to the site of the proposed implantation are contraindications to implantation.
Osteoporosis
Absence of posterior spinal elements including the pedicle, pars interarticularis, facet joints, spinous process and the majority of the lamina which make it unstable or not possible to place.
Any entity or conditions that totally preclude the possibility of fusion, i.e., cancer, kidney dialysis, or osteopenia, are relative contraindications.
Obesity (BMI ≥30)
Foreign body sensitivity
Alcoholism, or drug abuse
Subject with a cardiac pacemaker or other implanted electro medical device
Subject with known condition of drug abuse and/or alcoholism
Women who are either pregnant or nursing at the time of screening (to be verified by test in case of woman of child-bearing potential that do not practice medically acceptable methods of contraception)
Concurrent participation in another clinical trial using any investigational drug or device.
Mental disorders.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hanna Levy, Dr
Organizational Affiliation
ZygoFix
Official's Role
Study Director
Facility Information:
Facility Name
Pecs University Hospital
City
Pecs
ZIP/Postal Code
H-7623
Country
Hungary
12. IPD Sharing Statement
Learn more about this trial
Safety And Efficacy Assessment of the zLock Facet Fusion System- A Pilot Study
We'll reach out to this number within 24 hrs